NASDAQ · CRVO
CervoMed Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CRVO: Nov 6, 2026
CervoMed Inc. Common Stock is estimated to report earnings on 11/06/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.61. The reported EPS for the same quarter last year was $-0.84.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.61 | $-0.48 | $-0.73 | 3 |
| Dec 2026 | $-0.64 | $-0.48 | $-0.75 | 3 |
| Mar 2027 | $-0.62 | $-0.46 | $-0.78 | 2 |
| Jun 2027 | $-0.39 | $-0.36 | $-0.41 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks- Fintel · Oct 30, 3:28 AM EDTCervoMed Inc. Announces Publication of Two Peer-Reviewed Research Articles Supporting NeflamapimodCervoMed Inc. announced the publication of two peer-reviewed research articles supporting neflamapimod as a potential treatment for dementia with Lewy bodies. The first paper, published in Alzheimer's Research & Therapy, reports results from the placebo-controlled phase of th
- RTTNews · Oct 12, 8:03 AM EDTCervoMed Reports Initial NfL Findings; Clinical Data Expected In Q1 2027(RTTNews) – CervoMed Inc. (CRVO) announced initial results from the open-label portion of its Phase 2a clinical trial evaluating neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA), a rare form of frontotemporal dementia.
- RTTNews · Oct 12, 7:56 AM EDTCervoMed Reports NfL Biomarker Decline In Phase 2a Neflamapimod Trial(RTTNews) – CervoMed (CRVO) reported initial Phase 2a results showing a decline in plasma neurofilament light chain (NfL), a biomarker of neuronal damage, in patients with nonfluent variant primary progressive aphasia (nfvPPA).
- RTTNews · Sep 28, 7:54 AM EDTCervoMed Advances Neflamapimod With New Tablet Formulation And FDA Dose Flexibility(RTTNews) – CervoMed Inc. (CRVO) announced pharmacokinetic, regulatory, and manufacturing advances for neflamapimod, including a new 50 mg oral tablet formulation and the FDA's removal of a previous plasma drug exposure limit.
- RTTNews · Sep 10, 10:15 AM EDTCervoMed Presents Initial Phase 2a Results Of Neflamapimod In NfvPPA; Data Accepted For ISFTD 2026(RTTNews) – CervoMed Inc. (CRVO) announced that initial biomarker results from its ongoing Phase 2a clinical trial of Neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA) have been accepted for a late-breaking oral presentation at the International
- Zacks · Aug 6, 5:20 PM EDTJanux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue EstimatesJanux Therapeutics (JANX) delivered earnings and revenue surprises of -34.62% and -72.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 9:00 AM EDTEyePoint (EYPT) Reports Q2 Loss, Beats Revenue EstimatesEyePoint (EYPT) delivered earnings and revenue surprises of -18.48% and +102.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Aug 4, 12:57 PM EDTCervoMed Gains UK Innovation Passport For Advancing Neflamapimod In Lewy Body Dementia(RTTNews) – CervoMed Inc. (CRVO), a clinical-stage biotechnology company, on Tuesday reported that its drug candidate Neflamapimod has received an Innovation Passport to enter the UK's Innovative Licensing and Access Pathway (ILAP) for development in treating Dementia with Lewy B
- RTTNews · Jul 10, 3:53 AM EDTCervoMed Completes Enrollment In Phase 2a Study Of Neflamapimod For Nfv.Primary Progressive Aphasia(RTTNews) – CervoMed Inc. (CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, announced that it has completed enrollment in the Phase 2a study of its lead investigational candidate, Neflamapimod, for the treatment of Nonfluent Var
- RTTNews · Jun 22, 3:36 AM EDTCervoMed Unveils $10 Mln Offering Of Shares; Stock Down(RTTNews) – CervoMed Inc. (CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, announced and priced its offering of 2.5 million shares of common stock at $4.00 per share. The gross proceeds are expected to be $10 million.
- RTTNews · Jun 16, 11:02 PM EDTTop Biotech Gainers: CRVO On Watch, SLP Scooped Up, LNAI Back In Compliance, NTHI Advances NEO212(RTTNews) – Tuesday's top gainers include CervoMed, with key clinical trial catalysts ahead; Conexeu, which strengthened its leadership with board expansion; NeOnc, advancing its lead drug candidate into Phase 2 for aggressive brain tumours; and Simulations Plus, which is set to
- RTTNews · Jun 16, 9:28 AM EDTPre-Market Movers: SLBT, CRVO, CUPR Chart The Course(RTTNews) – Biotech companies are seeing significant pre-market activity this Tuesday, hinting at possible breakout opportunities. Pre-market movers give traders an early read on momentum, sentiment, and potential volatility for the trading day.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for CervoMed Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.